10-Q: Hi-Great Group Holding Company Reports Q2 2024 Results with Reduced Sales and Net Loss

Hi-Great Group Holding Company's Q2 2024 results show a decrease in sales and a net loss, alongside ongoing efforts to establish a sustainable business model.

Summary

• Hi-Great Group Holding Company reported a net loss of $23,310 for the six months ended June 30, 2024, compared to a net loss of $70,718 for the same period in 2023.
• Sales decreased to $24,330 for the first six months of 2024, down from $61,831 in the first six months of 2023.
• The company's cost of sales was $12,773 for the first six months of 2024, compared to $36,276 for the same period in 2023.
• Professional fees decreased significantly to $14,500 for the first six months of 2024, compared to $75,360 for the same period in 2023, due to lower legal and audit expenses.
• General and administrative expenses also saw a slight decrease to $5,448 for the first six months of 2024, compared to $5,913 for the same period in 2023, primarily due to reduced shipping costs.
• The company's accumulated deficit has increased to $862,289 as of June 30, 2024.
• The company is a development stage enterprise and is working to establish a new business and raise capital.
• The company has a licensing agreement with SellaCare, Inc. and is focusing on the KRAS gene for cancer research and also expanding into the cosmetic sector.

Sentiment

Score: 3

Explanation: The document reveals a struggling company with declining sales, ongoing losses, and weak cash reserves. While there are some positive notes about new business directions, the overall financial health and operational weaknesses are concerning.

Positives

• Professional fees decreased significantly, indicating cost-cutting measures.
• General and administrative expenses saw a slight decrease, suggesting improved operational efficiency.
• The company is exploring new business opportunities in the cosmetic sector and cancer research.

Negatives

• Sales have decreased significantly compared to the same period last year.
• The company continues to operate at a loss, with a net loss of $23,310 for the first six months of 2024.
• The accumulated deficit has increased to $862,289.
• The company's cash position is weak, with only $116 in cash at the end of the period.

Risks

• The company is a development stage enterprise and has not yet established a consistent source of revenue.
• The company is dependent on debt and equity financing to fund its operations.
• There is no assurance that the company will be able to raise additional capital or be successful in its business ventures.
• The company has identified material weaknesses in its internal controls, including a lack of an audit committee and segregation of duties.
• The company's ability to continue as a going concern is dependent on its ability to raise additional funding.

Future Outlook

The company is focusing on maximizing shareholder returns through dividends, sustainable growth, and potential appreciation in property value, while also exploring opportunities in the cosmetic sector and the KRAS gene research.

Management Comments

• Management is making efforts to raise additional funding until a registration statement relating to an equity funding facility is in effect.
• Management believes that it will be successful in its capital formation and planned operating activities.

Industry Context

The company's shift towards the KRAS gene research and the cosmetic sector reflects a move towards high-growth areas within the biotechnology and consumer goods industries, however, the company is still in a development stage and has not yet established a consistent source of revenue.

Comparison to Industry Standards

• The company's revenue of $24,330 for the first six months of 2024 is significantly lower than established companies in the health supplement and cosmetic sectors, such as Herbalife or Estee Lauder, which report revenues in the millions or billions.
• The company's net loss of $23,310 for the first six months of 2024 is not unusual for a development stage company, but it highlights the need for significant revenue growth to achieve profitability.
• The company's lack of an audit committee and segregation of duties are significant weaknesses compared to industry best practices for public companies, which typically have robust corporate governance structures.
• The company's cash balance of $116 is extremely low compared to industry standards, indicating a high risk of financial distress.

Management Changes

Corporate Governance

Related Party Transactions

• The company has a licensing agreement with SellaCare, Inc., which is controlled by the company's majority shareholder, requiring a 25% royalty payment on gross revenues.
• The company leases land from Sella Property, LLC, an entity controlled by the company's majority shareholder, with annual rent payments of $30,000.
• The company had a loan from Jung Ho Yang and Sellacare America, Inc. which have been paid.

Stakeholder Impact

• Shareholders are at risk due to the company's ongoing losses and weak financial position.
• Employees may face uncertainty due to the company's financial instability.
• Customers may be impacted by the company's ability to deliver products and services.
• Suppliers may face payment risks due to the company's financial challenges.
• Creditors are at risk due to the company's high debt and low cash reserves.

Next Steps

• The company needs to secure additional funding to continue operations.
• The company needs to develop and commercialize its products.
• The company needs to establish a sustainable revenue stream.
• The company needs to address the material weaknesses in its internal controls.

Key Dates

Keywords

financial results, quarterly report, net loss, revenue, KRAS gene, cosmetics, SellaCare, development stage, operating expenses, licensing agreement